U.S., April 10 -- ClinicalTrials.gov registry received information related to the study (NCT06918990) titled 'Treatment of Antibody-Mediated Rejection (ABMR) With CarBel' on April 02.
Brief Summary: The purpose of this study is to see:
1. If using these two drugs (carfilzomib and belatacept) together is safe
2. If the use of these two study drugs in addition to the usual immunosuppression for kidney transplant patients can improve your transplanted kidney function by lowering the antibodies you have against your transplanted kidney
3. If the study drugs effect the immune cells that were responding to your donor kidney. And, whether blood or urine tests can measure signs of inflammation and kidney cell injury
4. If using new computer te...